11. aprill 2026

Tervisekassa laiendas hüvitatavate ravimite nimekirja

The Health Insurance Fund expanded the list of reimbursable medications

Aprilli alguses lisati tervisekassa hüvitatavate ravimite nimekirja uusi ravimeid. Need on mõeldud nii soodus- kui ka haiglaravimiteks. Uued ravimid aitavad ravida vähki, silma- ja autoimmuunhaigusi ning vaimse tervise probleeme. Uued ravimid maksavad kokku üle 1,5 miljoni euro.

Soodusravimite nimekirja lisati ravim Ryjunea. See aitab laste . Lühinägevus on viimastel aastatel palju levinum. See tekib tavaliselt koolieas ja süveneb lapse kasvades. Mida varem see algab, seda tõsisem võib see täiskasvanueas olla. Ravim aitab vähendata tõsisemate silmahaiguste riski. Eestis on aastas umbes 300 patsienti, kes seda ravimit vajavad. Ryjunea on mugavam kui varasem ravim, kuid see maksab aastas ligi 150 000 eurot rohkem.

Teine uus ravim on Jakavi. Seda kasutatakse e ravis. See haigus võib tekkida pärast luuüdi siirdamist. Ravim aitab vähendada immuunsüsteemi reaktsiooni ja parandab patsiendi enesetunnet. Seda ravimit vajab aastas umbes 5-6 patsienti.

Aprillis lisati ka ravim Tentin, mis aitab ga (ATH) patsientidel. ATH on neuroloogiline häire, mis teeb lapsele raskeks keskenduda ja käituda. Ravim aitab parandada tähelepanu ja vähendada impulsiivsust. See on osa terviklikust ravist, mis sisaldab ka nõustamist ja tugiteenuseid.

Uusi ravimeid lisandus ka psoriaatilise artriidi, hiidrakulise arteriidi ja muude haiguste raviks. Lisaks on nüüd saadaval ravim immunoglobuliin Hyqvia e raviks ja seenküünhaiguse .

Haiglaravimite nimekirja lisati ka mitu uut ravimit. Need aitavad ravida raskeid ja harvaesinevaid haigusi. Näiteks lisati ravim Vabysmo, mis aitab kollatähni kärbumise korral. See haigus põhjustab nägemise kadumist vanemaealistel. Ravimit vajab umbes 1000 patsienti aastas.

Lisandus ka ravim raviks. See haigus põhjustab nägemise halvenemist ja liikumisraskusi. Ravim Ultomiris aitab pidurdada haiguse edasikulgemist. Eestis on seda vaja umbes viiel patsiendil.

Haiglaravimite valikusse lisati ka ravimid Libtayo ja Eylea. Libtayo aitab ravida i. Eylea on mõeldud e raviks.

At the beginning of April, new medications were added to the Health Insurance Fund's list of reimbursable drugs. These are intended for both outpatient and inpatient treatments. The new drugs will help treat cancer, eye and autoimmune diseases, as well as mental health issues. The new medications cost over €1.5 million in total.

The drug Ryjunea was added to the list of outpatient medications. It helps slow the progression of myopia in children. Myopia has become much more common in recent years. It usually develops during school years and progresses as the child grows. The earlier it starts, the more severe it can become in adulthood. The drug helps reduce the risk of more serious eye diseases. In Estonia, there are approximately 300 patients per year who need this medication. Ryjunea is more convenient than the previous drug, but it costs nearly €150,000 more per year.

Another new drug is Jakavi. It is used to treat graft-versus-host disease. This condition can occur after a bone marrow transplant. The drug helps reduce the immune system's response and improves the patient's well-being. Approximately 5-6 patients per year need this medication.

In April, the drug Tentin was also added, which helps patients with attention deficit hyperactivity disorder (ADHD). ADHD is a neurological disorder that makes it difficult for children to concentrate and behave. The drug helps improve attention and reduce impulsivity. It is part of a comprehensive treatment plan that also includes counseling and support services.

New medications were also added for the treatment of psoriatic arthritis, giant cell arteritis, and other diseases. Additionally, the immunoglobulin Hyqvia is now available for the treatment of immune deficiencies, and antifungal nail polish for fungal nail infections.

Several new drugs were also added to the list of inpatient medications. These help treat severe and rare diseases. For example, the drug Vabysmo was added to help in cases of age-related macular degeneration. This disease causes vision loss in the elderly. Approximately 1,000 patients per year need this medication.

The drug Ultomiris was added for the treatment of neuromyelitis optica spectrum disorder. This disease causes vision impairment and movement difficulties. Ultomiris helps slow the progression of the disease. In Estonia, it is needed by approximately five patients.

The inpatient medications list also included the drugs Libtayo and Eylea. Libtayo helps treat advanced lung cancer. Eylea is intended for the treatment of retinopathy in premature infants.